A novel tumor-vaccine cell therapy using bone marrow-derived dendritic cell type 1 and antigen-specific Th 1 cells

International Immunology

Volumn 15, Issue 7, 2003, Pages 837-843

  Sato, Marimo ^a   Chamoto, Kenji ^a   Nishimura, Takashi ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

Author keywords

Cell therapy; Cytotoxic T lympocyte; Dendritic cell type 1; Th 1; Tumor immunotherapy

Indexed keywords

CD4 ANTIGEN; CYTOKINE; GAMMA INTERFERON; OVALBUMIN; TUMOR ANTIGEN; TUMOR CELL VACCINE;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARTICLE; BONE MARROW CELL; CANCER IMMUNOTHERAPY; CELL TYPE; CLINICAL PROTOCOL; CONTROLLED STUDY; DENDRITIC CELL; DRUG EFFICACY; INOCULATION; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TH1 CELL; TUMOR CELL; TUMOR IMMUNITY; TUMOR REGRESSION; VACCINATION; VACCINE PRODUCTION;

EID: 0038350873     PISSN: 09538178     EISSN: None     Source Type: Journal    
DOI: 10.1093/intimm/dxg081     Document Type: Article

References (30)

1. Steinman, R. M. and Dhodapkar, M. 2001. Active immunization against cancer with dendritic cells: the near future. Int. J. Cancer 94:459.
2. Ashley, D. M., Faiola, B., Nair, S., Hale, L. P., Bigner, D. D. and Gilboa, E. 1997, Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. J. Exp. Med. 186:1177.
3. Thurner, B., Haendle, I., Röder, C., Dieckmann, D., Keikavoussi, P., Jonuleit, H., Bender, A., Maczek, C., Schreiner, D., Von den Driesch, P., Bröcker, E. B., Steinman, R. M., Enk, A., Kämpgen, E. and Schuler, G. 1999. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J. Exp. Med. 190:1669.
4. Shimizu, K., Fields, R. C., Giedlin, M. and Mule, J. J. 1999. Systemic administration of interleukin 2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines. Proc. Natl Acad. Sci. USA 96:2268.
5. Nikitina, Y. E. and Gabrilovich, D. I. 2001. Combination of γ-irradiation and dendritic cell administration induces a potent antitumor response in tumor-bearing mice: approach to treatment of advanced stage cancer. Int. J. Cancer 94:825.
6. h2 cells in tumor eradication in vivo. J. Exp. Med. 190:617.
7. Nishimura, T., Kitamura, H., Iwakabe, K., Yahata, T., Ohta, A., Sato, M., Takeda, K., Okumura, K., Van, L. K., Kawano, T., Taniguchi, M. and Nakui, M. 2000. The interface between innate and acquired immunity: glycolipid antigen presentation by CD1d-expressing dendritic cells to NKT cells induces the differentiation of antigen-specific cytotoxic T lymphocytes. Int. Immunol. 12:987.
8. Kadowaki, N. and Liu, YJ. 2002. Natural type I interferon-producing cells as a link between innate and adaptive immunity. Hum. Immunol. 63:1126.
9. Rissoan, M. C., Soumelis, V., Kadowaki, N., Grouard, G., Briere, F., De Waal Malefyt, R. and Liu, Y. J. 1999. Reciprocal control of T helper cell and dendritic cell differentiation. Science 283:1183.
10. + lymphoid dendritic cells. J. Exp. Med. 189:1981.
11. + CTL. J. Immunol. 167:3687.
12. h2-inducing cytokines. Immunol. Lett. 67:63.
13. Ohta, S., Tsukamoto, H., Watanabe, K., Makino, K., Kuge, S., Kanai, N., Habu, S. and Nishimura, T. 1995. Tumor-associated glycoantigen, sialy Lewis(a) as a target for bispecific antibody-directed adoptive tumor immunotherapy. Immunol. Lett. 44:35.
14. Van der Bruggen, P., Traversari, C., Chomoes, P., Lurquin, C., De Plean, E., Van den Eynde, B., Knuth, A. and Boon, T. 1991. A gene encoding an antigen recognized by cytotoxic T lymphocytes on a human melanoma. Science 254:1643.
15. Wang, R. F. and Rosenberg, S. A. 1999. Human tumor antigens for cancer vaccine development. Immunol. Rev. 170: 85.
16. Lee, K., Wang, E., Nielsen, M., Wunderlich, J., Migueles, S., Connors, M., Steinberg, S. M., Rosenberg, S. A. and Marincola, F. M. 1999. Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. J. Immunol. 163:6292.
17. He, L., Feng, H., Raymond, A., Kreeger, M., Zeng, Y., Graner, M., Whitesell, L. and Katsanis E. 2001. Dendritic-cell-peptide immunization provides immunoprotection against bcr-abl-positive leukemia in mice. Cancer Immunol, Immunother. 50:31.
18. Strome, S. E., Voss, S., Wilcox, R., Wakefield, T. L., Tamada, K., Flies, D., Chapoval, A., Lu, J., Kasperbauer, J. L., Padley, D., Vile, R., Gastineau, D., Wettstein, P. and Chen, L. 2002. Strategies for antigen loading of dendritic cells to enhance the antitumor immune response. Cancer Res. 62:1884.
19. Eggert, A. A., Schreurs, M. W., Boerman, O. C., Oyen, W. J., De Boer, A. J., Punt, C. J., Figdor, C. G. and Adema, G. J. 1999. Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration. Cancer Res. 59:3340.
20. Gabrilovich, D. I., Corak, J., Ciernik, I. F., Kavanaugh, D. and Carbone, D. P. 1997. Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin. Cancer Res. 3:483.
21. Scares, M. M., Mehta, V. and Finn, O. J. 2001. Three different vaccines based on the 140-amino acid MUC1 peptide with seven tandemly repeated tumor-specific epitopes elicit distinct immune effector mechanisms in wild-type versus MUC1-transgenic mice with different potential for tumor rejection. J. Immunol. 166:6555.
22. Steinman, R. M. 2001. Dendritic cells and the control of immunity: enhancing the efficiency of antigen presentation. Mt Sinai J. Med. 68:106.
23. + cytotoxic T lymphocyte priming capacity upon activation by T helper cell-independent or - dependent stimuli. J. Exp. Med. 192:145.
24. Lanzavecchia, A. 1998. Immunology. Licence to kill. Nature 393:413.
25. Medema, J. P., Schuurhuis, D. H., Rea, D., Van Tongeren, J., De Jong, J., Bres, S. A., Laban, S., Toes, R. E., Toebes, M., Schumacher, T. N., Bladergroen, B. A., Ossendorp, F., Kummer, J. A., Melief, C. J. M. and Offringa, R. 2001. Expression of the serpin serine protease inhibition 6 protects dendritic cells from cytotoxic T lymphocyte-induced apoptosis: differential modulation by T helper type 1 and type 2 cells. J. Exp. Med. 194:657.
26. Shimizu, K., Thomas, E. K., Giedlin, M. and Mule, J. J. 2001. Enhancement of tumor lysate- and peptide-pulsed dendritic cell-based vaccines by the addition of foreign helper protein. Cancer Res. 61:2618.
27. + regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol. Rev. 182:18.
28. Whiteside, T. L. 1999. Signaling defects in T lymphocytes of patients with malignancy. Cancer Immunol. Immonother. 48:346.
29. Perales, M. A., Blachere, N. E., Engelhorn, M. E., Ferrone, C. R., Gold, J. S., Gregor, P. D., Noffz, G., Wolchok, J. D. and Houghton, A. N. 2002. Strategies to overcome immune ignorance and tolerance. Semin. Cancer Biol. 12:63.
30. Uesaka, Y., Yu, W., Mukai, T., Gao, P., Yamaguchi, N., Murai, M., Matsushima, K., Obika, S., Imanishi, T., Higashibata, Y., Nomura, S., Kitamura, Y., Fujiwara, H. and Hamaoka, T. 2002. A pivotal role for CC chemokine receptor 5 in T-cell migration to tumor sites induced by interleukin 12 treatment in tumor-bearing mice. Cancer Res. 62:3571.